training.nih.gov
festival2000.nih.gov
training.nih.gov
It is not clear to me that this posting was for the year 2000 job fair. If anyone else can find a way to "date" this post, that would be great.......
DGI BioTechnologies, L.L.C. is a biotechnology-based research company formed in 1995 to develop its proprietary small
molecule drug lead discovery platform, called Diogenesis(TM). In today's modern pharmaceutical research family, DGI is
considered a biotech assay tool and small molecule discovery company. DGI's proprietary process provides a universal in vitro
assay platform for its small molecule drug lead discovery. The company is in the final stages of validating its new discovery
process. Using in-house developed site-directed assays, DGI is now running automated high-throughput screens (HTS) utilizing
large combinatorial small molecule chemical libraries provided by two of its partners.
Since becoming operational in 1996, the company has developed its Diogenesis(TM) service by first creating large and diverse
libraries of antibodies (GRABLIB(TM)) and peptides (RAPIDLIB(TM)), selecting specific entities which interact with and
regulate a number of receptors for protein hormones, and then labeling them for use in HTS assays. In addition, DGI has
obtained its first surrogate ligand 3D pharmacophore through NMR analysis of one of its anti-receptor peptides. DGI will
remain focused on identifying and optimizing via both HTS BioScreens(TM) and computer-based structural
CompuScreens(TM) promising small molecule drug leads which regulate protein:protein interactions. The company is currently
seeking royalty based licensing agreements and research partnerships with several pharmaceutical and biotechnology
companies.
DGI presently has 19 employees and discovery programs in anti-cancer, immunoregulators, neuroprotectives, and growth
enhancers. Its staff consists of individuals with academic and industry experience. The company has an active Board of
Scientific Advisors.
DGI is majority owned by New Brunswick Scientific Co. Inc. (NASDAQ:NBSC), a manufacturer of research equipment and
scientific instrumentation.
Positions Available:
Ph.D.-level Scientist,
Group Leader,
Director.
We seek talented individuals (biochemists, biological engineers, etc...) to join the high-throughput screening lab for novel
therapeutic entities. Background in the development of quantitative fluorescence- and radioactivity-based receptor binding
assays using modern assay technology is highly desirable. Familiarity with relational databases is a plus. Senior level candidates
should have a Ph.D. in Biology or related discipline, and at least 2-4 years of experience in high-throughput screening, and the
ability to manage a group of scientists. The candidates need to be able to select the robotics equipment, as well as design and
execute experimental protocols. All candidates should have excellent organization and communication skills, and the ability to
interact with scientists in an interdisciplinary setting.
The Company occupies a newly furnished 7,500-sq. ft. facility in the Edison, NJ headquarters of New Brunswick Scientific
Company, in an attractive location 30 miles southwest of New York City in the proximity of several major universities and
colleges. DGI offers competitive salaries and benefits, as well as an excellent opportunity for career growth in a stimulating
environment. |
